PUBLICATIONS

1. E. Erikçi, M. Gürsel, I. Gursel , Differential Immune Activation Following

Encapsulation of Immunostimulatory CpG Oligodeoxynucleotide in Nanoliposomes.
Biomaterials. 32(6):1715-23, 2011.
2. FC. Yagci, O. Aslan, M. Gursel, G. Tincer, Y. Ozdamar, K. Karatepe, KC. Akcali, I.
Gursel, Mammalian telomeric DNA suppresses endotoxin induced uveitis. J Biol Chem.
285:28806, 2010.
3. M. Gürsel, I. Gursel, HS. Mostowski, DM. Klinman, CXCL16 Influences the Nature
and Specificity of CpG-Induced Immune Activation, J. Immunol., 177:1575, 2006.
4.C. Coban, KJ. Ishii, M. Gürsel, DM. Klinman, N. Kumar, Effect of plasmid backbone
modification by different human CpG motifs on the immunogenicity of DNA vaccine
vectors, J.Leuko.Biol., 78:647, 2005.
5. H. Shirota, I. Gursel, M. Gürsel, D. M. Klinman, Suppressive oligodeoxynucleotides
protect mice from lethal endotoxic shock, J. Immunol, 174:4579, 2005.
6. T. Sugiyama, M. Gürsel, F. Takeshita, C. Coban, J. Conover, T. Kaisho, S. Akira,
DM. Klinman, CpG RNA: identification of single stranded RNA that stimulates human
CD14+CD11c+ monocytes, J. Immunol, 174:2273, 2005.
7. S. Ito, K.J. Ishii, M. Gürsel, H Shirota, A. Ihata, D. M. Klinman, CpG
oligodeoxynucleotides enhance neonatal resistance to listeria infection, J. Immunol,
174:777, 2005.
8. H. Shirota, M. Gürsel, D. M. Klinman, Suppressive oligodeoxynucleotides inhibit Th1
differentiation by blocking IFNg and IL-12 mediated signaling, J. Immunol,173:5002,
2004.
9. F. Takeshita, I. Gursel, K.J. Ishii, K. Suzuki, M. Gürsel, D. M. Klinman, Signal
transduction pathways mediated by the interaction of CpG DNA with toll-like receptor 9,
Semin. Immunol., 16:17, 2004.
10. K. J. Ishii, I. Gursel, M. Gürsel, D. M. Klinman, Immunotherapeutic utility of
stimulatory and suppressive oligodeoxynucleotides., Curr. Op. Mol. Ther. 6:166, 2004.
11. D. M. Klinman, R.A. Zeuner, H. Yamada, M. Gürsel, D. Currie, I. Gursel, Regulation
of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann. N.Y.
Acad. Sci. 1002:112, 2003.
12. I. Gursel*, M. Gürsel*, H. Yamada, F. Takeshita, K. J. Ishii, D. M. Klinman,
Repetitive elements present in mammalian telomeres suppress CpG DNA induced
immune activation, J. Immunol. 171:1393, 2003.
13. D. Verthelyi, M. Gürsel, RT. Kenney, JD. Lifson, S. Liu, J. Mican, DM. Klinman,
CpG Oligodeoxynucleotides Protect Normal and SIV-Infected Macaques from a
Leishmania Infection, J. Immunol, 170:4717, 2003.
14.RA. Zeuner, D. Verthelyi, M. Gürsel, KJ Ishii, and DM Klinman, Influence of
stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis.
Arthritis Rheum., 48:1701, 2003.
15. RA. Zeuner, DM. Klinman, G. Illei, CH. Yarboro, KJ. Ishii, M. Gürsel, D. Verthelyi.
Response of PBMC from lupus patients to stimulation by CpG oligondeoxynucleotides.
Rheumatology. 42:563, 2003.
16. H. Yamada, I. Gursel, F. Takeshita, J. Conover, KJ. Ishii, M. Gürsel, S. Takeshita,
and DM. Klinman, Effect of Suppressive DNA on CpG-Induced Immune Activation,
J. Immunol, 169:5590, 2002.
17. M. Gürsel, D. Verthelyi, D. M. Klinman, CpG oligodeoxynucleotides stimulate human
monocytes to mature into functional dendritic cells Eur. J. Immunol., 32:2617, 2002.
18. M. Gürsel, D. Verthelyi, I. Gursel, KJ. Ishii, DM. Klinman, Differential and competitive
activation of human immune cells by distinct classes of CpG oligodeoxynucleotides, J.
Leuko. Biol.,71:813, 2002.
19. D.M. Klinman, F. Takeshita, I. Gursel, C. Leifer, K.J. Ishii, D. Verthelyi, M. Gürsel
CpG DNA: recognition by and activation of monocytes, Microbes and Infection, 4:897,
2002.
20. KJ. Ishii, F.Takeshita, I. Gursel, M. Gürsel, J. Conover, A. Nussenzweig, DM.
Klinman, Potential role of PI3 kinases, rather than DNA-PK, in CpG DNA induced
immune activation, J. Exp. Med., 196:269, 2002.
21. F. Takeshita, C. Leifer, İ. Gürsel, M. Gürsel, K. J. Ishii, D. M. Klinman, Cutting Edge:
Role of Toll-like receptor-9 in CpG DNA induced activation of human cells. J. Immunol.
167:3555, 2001.
22. İ. Gürsel, M. Gürsel, K. J. Ishii, DM Klinman, Sterically stabilized cationic liposomes
improve the uptake and immunostimulatory activity of CpG oligonucleotides, J. Immunol.,
167:3224, 2001.
23. D. Verthelyi, K.J. Ishii, M. Gürsel, F. Takeshita, D. M. Klinman, Human peripheral
blood cells differentially recognize and respond to two distinct CpG motifs., J. Immunol.,
166:2372, 2001.
24. DM. Klinman, S. Kampstrup, D. Verthelyi, İ. Gürsel, KJ. Ishii, F. Takeshita, M. Gürsel,
Activation of the innate immune system by CpG:Therapeutic applications and safety
issues. Springer Semin. Immunopathol., 2: 173, 2000.
25. D. M. Klinman, K. J. Ishii, M. Gürsel, İ. Gürsel, S. Takeshita and F. Takeshita,
Immunotherapeutic applications of CpG containing oligodeoxynucleotides, Drug News
and Perspectives 13:289, 2000.
26. M. Gürsel, Tunca S, Ozkan M, Ozcengiz G, Alaeddinoglu G, Immunoadjuvant
action of plasmid DNA in liposomes. Vaccine 17:1376,1999.
27. M. Gürsel , G. Gregoriadis, The immunological co-adjuvant action of liposomal
interleukin-2: The role of mode of localization of the cytokine and antigen in the vesicles.
J. Drug Target., 5: 93, 1997.
28. M. Gürsel and G. Gregoriadis, Interleukin-15 acts as an immunological co-adjuvant
for liposomal antigen in vivo. Immunol. Lett., 55(3), 161-165, 1997.
29. M. Gürsel and G. Gregoriadis, The Immunological co-adjuvant action of liposomal
Interleukin-15, In: Vaccine Design: The role of Cytokine Networks, Eds. G.
Gregoriadis, A.C. Allison, and B. Mc.Cormack, Plenum Publishing Corporation, New
York, 175-180 (1997).
30. G. Gregoriadis, İ. Gürsel, M. Gürsel and B. Mc.Cormack, Liposomes as
immunological adjuvants and vaccine carriers. J. Contr. Rel., 41, 49-56, 1996.
31.T. Yoshioka, N. Skalko, M. Gürsel, G. Gregoriadis, A. T. Florence, A non-ionic
surfactant vesicle-in-water-in-oil (v/w/o) system:Potential uses in drug and vaccine
deliveryJ. Drug Target.2:533,1995.
32. M. Gürsel and V. Hasırcı, Influence of membrane components on the stability and
drug release properties of REVs: Light sensitive all-trans retinal, negatively charged
phospholipid dicetylphosphate and cholesterol., J. Microencapsulation, 12(6):661-669
(1995).
33. M. Gürsel and G. Gregoriadis, Interleukin-2 as a co-adjuvant for liposomal tetanus
toxoid., in: Vaccines: New Generation Immunological Adjuvants., Eds. G.
Gregoriadis, A.C. Allison, G. Poste and B. Mc.Cormack, Plenum Publishing
Corporation, New York, 45-50 (1995).
34. M. Gürsel and G. Gregoriadis, Immunoadjuvant action of liposomes containing
interleukin-2 as a co-adjuvant, ‘International Symposium on Controlled Release of
Bioactive Materials’, 22:572-573 (1995).